| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000009987 |
| Receipt No. | R000007650 |
| Official scientific title of the study | Effects of miglitol on visceral fat distribution and cardiovascular risk factors in subjects with the metabolic syndrome |
| Date of disclosure of the study information | 2013/02/08 |
| Last modified on | 2018/08/13 (Ver. 4) |
| Basic information | ||
| Official scientific title of the study | Effects of miglitol on visceral fat distribution and cardiovascular risk factors in subjects with the metabolic syndrome | |
| Title of the study (Brief title) | miglitol and metabolic syndrome | |
| Region |
|
|
| Condition | ||
| Condition | Metabolic syndrome | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To clarify effects of miglitol, alpha-glucosidase inhibitor, on fat distribution and cardiovascular risk factors |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Exploratory |
| Trial characteristics_2 | Pragmatic |
| Developmental phase | Not applicable |
| Assessment | |
| Primary outcomes | Changes in visceral fat distribution and cardiovascular risk factors |
| Key secondary outcomes | |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Open -but assessor(s) are blinded |
| Control | No treatment |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Life-style modification | |
| Interventions/Control_2 | Miglitol-treatment and Life-style modification | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | Metabolic syndrome (IDF criteria). In the IDF criteria, subjects to be defined as metabolic syndrome have: abdominal obesity (modified Japanese criteria, waist circumference >=90 cm in men and >=80 cm in women), plus any two of the following four factors; 1) hypertriglyceridemia (serum triglyceride concentration >=150 mg/dl [1.69 mmol/l]); 2) low HDL cholesterol (serum HDL cholesterol concentration <40 mg/dl [1.04 mmol/l] in men and <50 mg/dl [1.29 mmol/l] in women); 3) elevated blood pressure: systolic blood pressure >=130 mmHg and/or diastolic blood pressure >=85 mmHg; 4) high fasting glucose: serum glucose concentration >=100 mg/dl (5.6 mmol/l). | |||
| Key exclusion criteria | Patients with a history of cardiovascular or cerebrovascular disease, hepatic or renal disease, diabetes mellitus or heavy smoker were excluded. | |||
| Target sample size | 2 | |||
| Research contact person | |
| Name of lead principal investigator | Michio Shimabukuro, MD, PhD |
| Organization | Tomishiro Chuo Hospital |
| Division name | Diabetes and Life-style Related Disease Center |
| Address | Ueda 25, Tomishiro City, Okinawa, Japan |
| TEL | |
| Public contact | |
| Name of contact person | |
| Organization | Tomishiro Chuo Hospital |
| Division name | Diabetes and Life-style Related Disease Center |
| Address | |
| TEL | |
| Homepage URL | |
| Sponsor | |
| Institute | Department of Cardio-Diabetes Medicine, The University of Tokushima Graduate School of Health Biosciences |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Department of Cardio-Diabetes Medicine, The University of Tokushima Graduate School of Health Biosciences |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Partially published |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000007650 |